MAPLE GROVE, Minn., Oct. 11, 2017 /PRNewswire/ -- Upsher-Smith Laboratories, LLC. (Upsher-Smith) today announced the launch of Exemestane Tablets, 25 mg. The company recently received U.S. Food and ...
BOCA RATON, Fla., Feb. 27, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug ...
San Antonio, December 8 – Pfizer announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for AROMASIN ...
Sept. 19, 2005 — The European Commission has approved exemestane tablets for the treatment of estrogen receptor–positive invasive early breast cancer after two to three years of initial adjuvant ...
Reductions in bone mineral density over time are seen with the use of Aromasin. For more information on Pfizer Oncology, including full prescribing information for Sutent (sunitinib malate) and ...
Pfizer announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to Aromasin (exemestane tablets) after taking tamoxifen for 2-3 years experienced a ...
Selective estrogen-receptor modulators (tamoxifen [Nolvadex, Soltamox], raloxifene [Evista]) have been shown to reduce the risk of breast cancer in postmenopausal women, but also have been associated ...
Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. Background: Resistance to endocrine therapy (ET) is a common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback